Back20/20 Biolabs Common Stock Overview
20/20 Biolabs, Inc. Common Stock

20/20 Biolabs Common Stock Debt to Equity

Valuation check: AIDX's debt-to-equity ratio is 0.64, above the sector sector average of 0.2.

Get informed when a big investor buys or sells

+ Follow

Debt to Equity

0.64

Debt to Equity

0.64

Debt-to-Equity ratio measures a company's financial leverage by comparing its total debt to shareholder equity. A lower D/E ratio generally indicates a more financially stable company with less risk.

Debt to Equity (Comparison Companies)

Loading

Debt to Equity History

Loading

Debt to Equity Comparison

Loading

20/20 Biolabs Common Stock (AIDX) FAQ

The latest debt-to-equity ratio for AIDX is 0.64. That is above the sector sector average of 0.2. Investors often review this figure alongside 20/20 Biolabs Common Stock's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, AIDX currently prints 0.64 for debt-to-equity ratio, while the sector average sits near 0.2. That is roughly 220.2% above the sector mean. Large gaps often invite a closer look at 20/20 Biolabs Common Stock's growth, margins, and balance sheet.

A debt-to-equity ratio of 0.64 for 20/20 Biolabs Common Stock is not 'good' or 'bad' on its own. Compare it with the peer average (0.2) and with AIDX's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting AIDX's debt-to-equity ratio (0.64), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.